HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on NovoCure (NASDAQ:NVCR) and raises the price target from $21 to $22.
February 22, 2024 | 7:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on NovoCure and raises the price target from $21 to $22.
The upgrade in the price target by HC Wainwright & Co. reflects a positive outlook on NovoCure's stock, likely due to favorable analysis by the firm's analyst, Emily Bodnar. This kind of analyst action typically leads to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100